Loading...
XKRX011000
Market cap132mUSD
Jan 07, Last price  
2,410.00KRW
1D
-3.21%
1Q
0.21%
Jan 2017
-56.98%
Name

Gene One Life Science Inc

Chart & Performance

D1W1MN
XKRX:011000 chart
P/E
—
P/S
4.79
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.98%
Rev. gr., 5y
3.23%
Revenues
40.20b
-17.48%
10,090,159,00013,974,021,00015,003,954,00023,281,689,00027,737,197,30019,410,461,05020,657,215,57024,625,225,86028,364,784,67031,371,459,15027,171,385,67034,292,567,64041,241,251,46041,502,728,97038,700,355,31048,718,300,17040,202,911,100
Net income
-77.77b
L+103.85%
-2,902,726,000-5,849,328,000-8,415,948,000-7,592,468,000-4,937,077,000-8,888,478,000-8,362,870,000-6,491,730,0001,413,762,890-15,598,929,630-23,729,654,920-11,897,642,780-7,618,562,790-18,648,412,110-15,951,499,510-38,150,069,800-77,768,041,880
CFO
-21.74b
L-9.83%
-3,269,203,000-3,147,292,000-3,040,938,000-3,876,427,000-2,874,458,200-6,202,869,980-2,347,273,130-4,158,524,800778,497,730-12,388,731,200-4,040,042,510-7,268,957,370-1,270,007,140-15,915,810,140-4,849,167,610-24,113,048,350-21,743,560,700

Profile

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.
URL
https://www.genels.com/
IPO date
Nov 16, 1987
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
40,202,911
-17.48%
48,718,300
25.89%
Cost of revenue
69,773,005
58,975,910
Unusual Expense (Income)
NOPBT
(29,570,094)
(10,257,610)
NOPBT Margin
Operating Taxes
113,447
95,792
Tax Rate
NOPAT
(29,683,541)
(10,353,402)
Net income
(77,768,042)
103.85%
(38,150,070)
139.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,469,986
379,479
BB yield
-1.12%
-0.07%
Debt
Debt current
4,801,494
14,157,351
Long-term debt
20,839,731
12,928,505
Deferred revenue
1,239,720
1,421,301
Other long-term liabilities
2,729,215
172,550
Net debt
12,976,316
12,284,671
Cash flow
Cash from operating activities
(21,743,561)
(24,113,048)
CAPEX
(5,653,047)
(45,407,993)
Cash from investing activities
25,891,861
8,055,142
Cash from financing activities
(8,285,090)
7,012,570
FCF
4,461,660
(49,407,033)
Balance
Cash
9,988,212
45,602,685
Long term investments
2,676,698
(30,801,500)
Excess cash
10,654,764
12,365,270
Stockholders' equity
(101,110,271)
(27,322,542)
Invested Capital
233,728,002
230,006,988
ROIC
ROCE
EV
Common stock shares outstanding
77,750
77,486
Price
2,840.00
-60.22%
7,140.00
-55.93%
Market cap
220,809,705
-60.09%
553,248,027
-54.00%
EV
233,786,020
565,532,698
EBITDA
(16,793,818)
(4,833,930)
EV/EBITDA
Interest
1,179,626
7,309,293
Interest/NOPBT